Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Stephen Benoit will be presenting an overview of the company's business at the 2nd annual BIO Convention taking place October 24-25 in China. Hosted by the Biotechnology Industry Organization (BIO), the Convention will bring together executives from biotechnology, pharmaceutical companies and investment firms from North America, Europe and Asia to meet and explore business opportunities with China's emerging biotech sector. Mr. Benoit will present on Thursday, October 25 at 9:30 a.m. in Function Room 3 at the Kerry Hotel in Pudong, Shanghai.
MSDC is developing novel small molecules (mTOT Modulators) to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially insulin resistance and type 2 diabetes.
http://www.heraldonline.com/2012/10/17/4344462/metabolic-solutions-development.html
MSDC is developing novel small molecules (mTOT Modulators) to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially insulin resistance and type 2 diabetes.
http://www.heraldonline.com/2012/10/17/4344462/metabolic-solutions-development.html